Annexon broadens autoimmune franchise with advancement of third anti-c1q product candidate and strategic expansion into new autoantibody-driven diseases

Advancing subcutaneous anx009 candidate into phase 1b program in lupus nephritis

ANNX Ratings Summary

ANNX Quant Ranking